文献速递慢病防控与筛查免疫规划

NTHi蛋白疫苗在COPD成人中的2期临床试验

Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
PubMed 文献 · Vaccine · 2019-08-22

这项2期观察者盲法对照试验将145例40-80岁中重度COPD且既往有急性加重史的患者按1:1随机分配,间隔60天接种两剂含NTHi抗原(PD、PE-PilA)与AS01佐剂的试验疫苗或安慰剂。疫苗组反应原性高于安慰剂,但多数为轻中度;抗体浓度在每剂后30天升高,至第2剂后13个月仍高于基线。探索性分析显示第2剂后一年内中重度急性加重年发生率疫苗组1.49、安慰剂组1.73,疫苗效力估计13.3%(95%CI -24.2至39.5;p=0.44),无统计学显著性。

要点

  • NTHi疫苗在COPD成人中安全性可接受,反应原性高于安慰剂但多为轻中度。
  • 疫苗诱导的抗PD、抗PE和抗PilA抗体及特异性CD4+ T细胞反应高于基线。
  • 中重度急性加重年发生率疫苗组1.49 vs 安慰剂1.73,疫苗效力13.3%(无统计学显著性)。

核心结论

  • NTHi疫苗在COPD成人中具有可接受的安全性和反应原性,并诱导良好免疫原性。
  • 探索性分析未显示中重度急性加重年发生率的统计学显著降低。

研究设计与样本

  • 2期、观察者盲法、对照试验(NCT02075541),145例40-80岁中重度COPD且有既往急性加重史的患者按1:1随机分配。
  • 受试者间隔60天接种两剂NTHi疫苗或安慰剂,均叠加标准治疗。

主要发现

  • 接种后7天内反应原性在NTHi疫苗组高于安慰剂组,多数征集性不良事件为轻中度。
  • 接种后30天内至少报告1项非征集性不良事件的比例:疫苗组54.8%、安慰剂组51.4%。
  • 1例严重不良事件(安慰剂组)被研究者评估为疫苗相关。
  • 抗PD、抗PE和抗PilA几何平均抗体浓度在每剂后30天升高,随后下降,但至第2剂后13个月仍高于基线(置信区间不重叠)。
  • 特异性CD4+ T细胞频率在接种两剂后升高并保持高于基线。

关键数值与推荐

  • 第2剂后一年内中重度急性加重年发生率:疫苗组1.49 vs 安慰剂组1.73。
  • 估计疫苗效力13.3%(95%CI -24.2至39.5;p=0.44)。

临床怎么用

  • 该疫苗在COPD成人中安全性可接受且具免疫原性,但现有数据尚不支持其降低急性加重的临床效力。
  • 需更大规模研究进一步评估对COPD急性加重的影响。

局限性

  • 探索性分析中疫苗效力无统计学显著性(95%CI跨0,p=0.44)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Loss of airway microbial diversity is associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation in chronic obstructive pulmonary disease (COPD). We assessed the safety and immunogenicity of an investigational vaccine containing NTHi antigens, recombinant protein D (PD) and combined protein E and Pilin A (PE-PilA), and AS01 adjuvant in adults with moderate/severe COPD and prior exacerbations. In this phase 2, observer-blind, controlled trial (NCT02075541), 145 COPD patients aged 40-80 years randomly (1:1) received two doses of NTHi vaccine or placebo 60 days apart, on top of standard care. Reactogenicity in the 7-day post-vaccination period was higher following NTHi vaccine than placebo. Most solicited adverse events (AEs) were mild/moderate. At least one unsolicited AE was reported during the 30-day post-vaccination period by 54.8% of NTHi vaccine and 51.4% of placebo recipients. One serious AE (placebo group) was assessed by the investigator as vaccine-related. Anti-PD, anti-PE and anti-PilA geometric mean antibody concentrations increased up to 30 days after each NTHi vaccine dose, waned thereafter, but remained higher than baseline (non-overlapping confidence intervals) up to 13 months post-dose 2. The frequency of specific CD4+ T cells increased following two doses of NTHi vaccine and remained higher than baseline. Exploratory analysis showed a statistically non-significant lower yearly rate of moderate/severe exacerbations in the NTHi vaccine group than following placebo (1.49 versus 1.73) in the one-year period post-dose 2, with estimated vaccine efficacy of 13.3% (95% confidence interval -24.2 to 39.5; p = 0.44). The NTHi vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in adults with COPD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wilkinson TMA, Schembri S, Brightling C, et al. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial. Vaccine. 2019. PMID: 31447126. doi:10.1016/j.vaccine.2019.07.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。